Treatment of tinea imbricata: A randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole

British Journal of Dermatology

Volumn 150, Issue 1, 2004, Pages 119-126

  Wingfield, A B ^a   Fernandez Obregon, A C ^b   Wignall, F S ^c   Greer, D L ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hudson Dermatology and Skin Cancer Center   (United States)

^c Box R ^*  (Indonesia)

Author keywords

Tinea imbricata; Tokelau; Trichophyton concentricum

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; LIVER ENZYME; TERBINAFINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYCOSIS; DISEASE ACTIVITY; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHOOL CHILD; SIDE EFFECT; TINEA; TINEA IMBRICATA;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHILD; FEMALE; FLUCONAZOLE; GRISEOFULVIN; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; NAPHTHALENES; PROSPECTIVE STUDIES; SKIN; TINEA; TREATMENT OUTCOME;

EID: 1242297712     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.05643.x     Document Type: Article

References (15)

1. Hay RJ, Reid S, Talwat E, Macnamara K. Endemic tinea imbricata: a study in Goodenough Island, Papua New Guinea. Trans R Soc Trop Med Hyg 1984; 78: 246-51.
2. Rippon JW. Dermatophytosis and dermatomycosis. In: Medical Mycology (Rippon JW, eds). Philadelphia: W.B. Saunders, 1988: 205-7.
3. Elewski BE, Boni E. The superficial mycoses, the dermatophytoses, and select dermatomycoses. In: Cutaneous Fungal Infections (Elewski BE, ed.). Malden, MA: Blackwell Science, Inc., 1998: 35-7.
4. Logan RA, Kobza-Black A. Tinea imbricata in a British nurse. Clin Exp Dermatol 1988; 13: 232-3.
5. Hay RJ. Tinea imbricata. In: Current Topics in Medical Mycology (McGinnis MR, ed.). New York: Springer-Verlag, 1988: 55-72.
6. Ravine D, Turner KJ, Alpers MP. Genetic inheritance of susceptibility to tinea imbricata. J Med Genet 1980; 17: 342-8.
7. Serjeantson S, Lawrence G. Autosomal recessive inheritance of susceptibility of tinea imbricata. Lancet 1977; i: 13-15.
8. Hay RJ. Tinea imbricata: the factors affecting persistent dermatophytosis. Int J Dermatol 1985; 9: 562-4.
9. Hay RJ, Reid S, Talwat E, Macnamara K. Immune responses of patients with tinea imbricata. Br J Dermatol 1983; 108: 581-6.
10. Hay RJ, Shennan G. Antibody responses in tinea imbricata: the role of IgE. Trans R Soc Trop Med Hyg 1984; 78: 653-5.
11. Physicians' Desk Reference®. 54th edn. Montvale, NJ: Medical Economics Data Production Company. 2000: 1457-60, 2020-1. 2338-42, 2802-3.
12. Halde C, Sik OL. Tinea imbricata treated with griseofulvin. Am J Trop Med Hyg 1965; 14: 1062-5.
13. Budimulja U, Kuswadji K, Bramono S et al. A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatol 1994; 130 (Suppl. 43): 29-31.
14. Gupta AK. Systemic antifungal agents. In: Comprehensive Dermatologic Drug Therapy (Wolverton SE, eds). Philadelphia: W.B. Saunders, 2001: 55-75.
15. Epstein WL, Shah VP, Riegelman S. Griseofulvin levels in stratum corneum. Study after oral administration in man. Arch Dermatol 1972; 106: 344-8.